Diagnostic Company Acquisition to Ease Market Entry and Shorten Development Time for New Tests
|
By LabMedica International staff writers Posted on 15 Sep 2015 |
Two North American manufacturers of rapid diagnostic tests are combining in order to pool their products for rapid entry into the diagnostic product market and to boost development of new tests.
NOWDiagnostics Inc. (Springdale, AR, USA) recently completed the acquisition of ZBx Corporation (Toronto, Canada). NOWDiagnostics manufactures and sells a line of blood-based rapid tests that allow health care providers to conduct simple-to-use, highly accurate tests for a variety of ailments and diseases. ZBx Corporation, with a customer base that includes Canada, Europe, Asia, Africa, South America and Mexico, develops and manufactures rapid format, point-of-care diagnostic products in both the human and veterinary fields.
“We are excited about the growth of NOWDiagnostics and what this means for point-of-care testing and the healthcare industry in general. Our acquisition of ZBx, with its deep product portfolio, experienced personnel, and broad capabilities, will help us increase the speed at which we are currently developing our tests,” said Kevin Clark, CEO of NOWDiagnostics. “The tests we are creating have the potential to revolutionize current medical test protocols and to lower costs to insurance companies and, ultimately, consumers.”
Related Links:
NOWDiagnostics
ZBx Corporation
NOWDiagnostics Inc. (Springdale, AR, USA) recently completed the acquisition of ZBx Corporation (Toronto, Canada). NOWDiagnostics manufactures and sells a line of blood-based rapid tests that allow health care providers to conduct simple-to-use, highly accurate tests for a variety of ailments and diseases. ZBx Corporation, with a customer base that includes Canada, Europe, Asia, Africa, South America and Mexico, develops and manufactures rapid format, point-of-care diagnostic products in both the human and veterinary fields.
“We are excited about the growth of NOWDiagnostics and what this means for point-of-care testing and the healthcare industry in general. Our acquisition of ZBx, with its deep product portfolio, experienced personnel, and broad capabilities, will help us increase the speed at which we are currently developing our tests,” said Kevin Clark, CEO of NOWDiagnostics. “The tests we are creating have the potential to revolutionize current medical test protocols and to lower costs to insurance companies and, ultimately, consumers.”
Related Links:
NOWDiagnostics
ZBx Corporation
Latest Industry News
- Natera to Present Data on MRD-Guided Cancer Care at ASCO 2026
- Fujifilm Integrates Structured Reporting into Digital Pathology Workflow
- Strategic Collaboration Advances RNA Foundation Models for Precision Oncology
- Partnership Brings Single-Cell Analysis into Clinical Oncology Workflows
- Partnership Aims to Bring Risk-Guided CKD Care to Health Systems
- AI-Powered Multi-Functional Analyzer Wins German Innovation Award
- Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
- FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy
- CareDx Expands Precision Oncology Portfolio with Naveris Acquisition
- Thermo Fisher Scientific to Sell Microbiology Business to Astorg
- Collaboration Expands Access to Rapid Metagenomic Diagnostics for Complex Infections
- Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
- QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
- QIAGEN Showcases Integrated Sample-to-Insight Oncology Solutions at AACR 2026
- Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
- Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring
Channels
Clinical Chemistry
view channel
Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
Primary central nervous system lymphoma (PCNSL) is a rare malignancy of the brain, spinal cord, and eyes with delayed diagnosis and poor outcomes. Current fluid-based testing using interleukin measurements... Read more
New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at an advanced stage and remains one of the most lethal solid tumors. Clinicians commonly use serum carbohydrate antigen 19-9 (CA19-9) to... Read moreMolecular Diagnostics
view channel
Gene Fusion Patterns May Flag High Risk Solitary Fibrous Tumors
Solitary fibrous tumor (SFT) is a rare subtype of sarcoma, a cancer that develops in connective tissues such as fat, muscle, blood vessels, and fibrous tissue. SFTs most commonly arise in the chest cavity... Read more
New RNA Origami Method Supports Faster Targeted Testing for Repeat Expansion Disorders
Repeat expansion disorders drive conditions such as myotonic dystrophy, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), yet accurately sizing the mutated sequences remains difficult.... Read moreHematology
view channel
Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read moreImmunology
view channel
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read more
Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring
Lung transplant recipients face some of the highest rates of acute cellular rejection, and routine surveillance often relies on repeated surgical biopsies. These procedures can cause complications such... Read moreMicrobiology
view channel
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read more
New AMR Assay Supports Rapid Infection Control Screening in Hospitals
As antimicrobial resistance spreads worldwide, healthcare-associated infections are placing a growing burden on hospitals, increasing the need for faster and broader diagnostic solutions.... Read morePathology
view channel
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read moreTechnology
view channel
AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
Clinical laboratories and research groups face increasingly complex molecular workflows and expanding technical documentation spread across multiple systems. Fragmented digital tools can slow experiment... Read more




.jpg)



